Immunotherapy for Infectious Diseases

178 Connick
114. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirusspecific
CD4� T-lymphocyte responses after ganciclovir and highly active antiretroviral
therapy in individuals infected with HIV-1. Nat Med 1998; 4:953–956.
115. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and
human immunodeficiency virus-1-specific cell-mediated immunity during highly active
antiretroviral therapy. J Infect Dis 1999; 180:76–86.
116. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression
of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
AIDS 2000; 14:761–770.
117. Valdez H, Smith K, Landay A, et al. Response to immunization with recall and neoantigens
after prolonged administration of an HIV-1 protease inhibitor-containing regimen.
AIDS 2000; 14:11–21.
118. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed-type hypersensitivity skin testing predicts
progression to AIDS in HIV-infected patients. Ann Intern Med 1993; 119:177–184.
119. Thompson NJ, Glasroth J, Sinder D, et al. The booster phenomenon in serial tuberculin
testing. Am Rev Respir Dis 1979; 119:587–597.
120. Fleming C, Cilento J, Steger K, McNamara E, Pelton S, Craven D. Immunogenicity of
revaccination with penumococcal vaccine in HIV-infected patients on combination antiretroviral
therapy. In: 7th Conference on Retroviruses and Opportunistic Infections. San
Francisco, 2000 [Abstract 249].
121. Weiss PJ, Wallace MR, Oldfield EC, O’Brien J, Janoff EN. Response of recent human
immunodeficiency virus seroconverters to the penumococcal polysaccharide vaccine and
Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995; 171:1217–1222.
122. Angel JB, Parato KG, Kumar A, et al. Progressive human immunodeficiency virusspecific
immune recovery with prolonged viral suppression. J Infect Dis 2001;
183:546–554.
123. Andre P, Klenerman P, Groettrup M, et al. An inhibitor of HIV-1 protease blocks proteasome
activity, antigen presentation and CD8 T cell responses. Proc Natl Acad Sci USA
1998; 95:13120–13125.
124. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the cell-mediated
immune response in human immunodeficiency virus infection. J Virol 1987; 61:2017–2023.
125. Berzofsky JA, Bensussan A, Cease KB, et al. Antigenic peptides recognized by T lymphocytes
from AIDS viral envelope-immune human. Nature 1988; 334:706–708.
126. Krowka JF, Stites DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency
virus antigens in vitro. J Clin Invest 1989; 83:1198–1203.
127. Schwartz D, Sharma U, Busch M, et al. Absence of recoverable infectious virus and
unique immune responses in an asymptomatic HIV� long term survivor. AIDS Res Hum
Retroviruses 1994; 10:1703–1711.
128. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4� T cell
responses associated with control of viremia. Science 1997; 278:1447–1450.
129. Plana M, Garcia F, Gallart T, et al. Lack of T-cell proliferate response to HIV-1 antigens
after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology
Study Group of Spanish EARTH-1 Study. Lancet 1998; 352:1194–1195.
130. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically
HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397–403.
131. Haslett PA, Nixon DF, Shen Z, et al. Strong human immunodeficiency virus (HIV)specific
CD4� T cell responses in a cohort of chronically infected patients are associated
with interruptions in anti-HIV chemotherapy. J Infect Dis 2000; 181:1264–1272.
132. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4� T cells are detectable
in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.
Nat Med 1999; 5:518–525.